These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29446744)

  • 1. Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists.
    AlSheyyab RY; Al-Taani BM; Obeidat RM; Alsmadi MM; Masaedeh RK; Sabat RN
    Curr Drug Deliv; 2018; 15(5):602-609. PubMed ID: 29446744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on the effects of gonadotropin-releasing hormone analogues in the inhibition of ovarian cancer transplanted tumors and in the protection of ovarian function after chemotherapy on nude mice].
    Zhang Y; Lu ZY; Yan XH; Wang JJ; Feng WW; Ding JX; Hua Kq
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):892-7. PubMed ID: 22333277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists.
    Tan O; Bukulmez O
    Curr Opin Obstet Gynecol; 2011 Aug; 23(4):238-44. PubMed ID: 21666463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral delivery of oil-based formulation for a novel synthetic cationic peptide of GnRH (gonadotropin-releasing hormone) antagonist for prostate cancer treatment.
    Zhang G; Wang T; Gao L; Quan D
    Int J Pharm; 2013 Jun; 450(1-2):138-44. PubMed ID: 23623791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol.
    Griesinger G; Dawson A; Schultze-Mosgau A; Finas D; Diedrich K; Felberbaum R
    Fertil Steril; 2006 Mar; 85(3):791-3. PubMed ID: 16500366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
    Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
    Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH antagonist cetrorelix prevents sexual maturation of peripubertal male rats.
    Roth C; Leonhardt S; Seidel C; Lakomek M; Wuttke W; Jarry H
    Exp Clin Endocrinol Diabetes; 2000; 108(5):358-63. PubMed ID: 10989955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH antagonists in the treatment of advanced prostate cancer.
    Pommerville PJ; de Boer JG
    Can J Urol; 2010 Apr; 17(2):5063-70. PubMed ID: 20398443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic delivery of cetrorelix to rats by a new aerosol delivery system.
    Lizio R; Klenner T; Sarlikiotis AW; Romeis P; Marx D; Nolte T; Jahn W; Borchard G; Lehr CM
    Pharm Res; 2001 Jun; 18(6):771-9. PubMed ID: 11474780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle.
    Evans MJ; Alexander SL; Irvine CH; Kitson NE; Taylor TB
    Anim Reprod Sci; 2011 Sep; 127(3-4):188-96. PubMed ID: 21889856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial.
    Steward RG; Gill I; Williams DB; Witz CA; Griffith J; Haddad GF
    Fertil Steril; 2011 Jan; 95(1):434-6. PubMed ID: 20810107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetrorelix, a gonadotropin-releasing hormone antagonist, induces the expression of melatonin receptor 1a in the gonadotropin-releasing hormone neuronal cell line GT1-7.
    Ishii H; Sato S; Yin C; Sakuma Y; Kato M
    Neuroendocrinology; 2009; 90(3):251-9. PubMed ID: 19641296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose.
    Ponzano A; Colangelo EC; Di Biase L; Romani F; Tiboni GM
    Gynecol Endocrinol; 2017 Mar; 33(3):208-211. PubMed ID: 27922279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone administration route in gonadotropin-releasing hormone antagonist cycles.
    Bahceci M; Ulug U
    Fertil Steril; 2010 Aug; 94(3):e47; author reply e48. PubMed ID: 20627239
    [No Abstract]   [Full Text] [Related]  

  • 19. Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance.
    Schwach G; Oudry N; Giliberto JP; Broqua P; Lück M; Lindner H; Gurny R
    Eur J Pharm Biopharm; 2004 May; 57(3):441-6. PubMed ID: 15093591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
    Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
    Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.